Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study

Table 2 Factors impacting adherence

Factor	Objective adherence group			Ordinal regression
Factor	Low n = 15	Medium n = 18	High n = 20	OR	95% CI	p
Patient age, years	41.0 (31.5–48.0)	48.5 (36.5–54.8)	53.5 (42.0–63.0)	1.064	1.016–1.114	0.008
Last known EDSS score^a	1.5 (1.0–2.0)	2.0 (1.5–3.3)	3.0 (2.0–3.8)	1.937	1.197–1.937	0.008
Neurologists’ estimations of adherence	10.0 (8.0–10.0)	9.0 (9.0–10.0)	10.0 (9.0–10.0)	1.528	1.019–2.291	0.04
Previous MS therapy	20.0%	33.0%	0.0%	0.344	0.089–1.340	0.124
Patient’s perceived relevance of ease of administration with RebiSmart®	9.0 (7.5–9.5)	10.0 (9.3–10.0)	10.0 (10.0–10.0)	1.578	1.080–2.307	0.018
Patient’s perceived relevance of storage of RebiSmart®	8.0 (5.5–8.0)	8.0 (5.3–10.0)	10.0 (8.0–10.0)	1.528	1.019–2.291	0.04
Being well informed about features of RebiSmart®	10.0 (9.0–10.0)	10.0 (10.0–10.0)	10.0 (10.0–10.0)	3.638	1.201–11.018	0.022
Patient’s perceived relevance of treatment in delaying progression of disease	10.0 (10.0–10.0)	10.0 (10.0–10.0)	10.0 (10.0–10.0)	1.063	0.644–1.753	0.812
Importance of frequency of administration	8.0 (7.0–9.0)	8.5 (6.3–10.0)	10.0 (5.0–10.0)	1.008	0.808–1.259	0.941

Data were analyzed by ordinal regression and are reported as median (interquartile range, Q1–Q3), with the exception of ‘Previous MS therapy’ which is reported as percentage of ‘yes’ responses. P-values that were considered significant (p < 0.05) are in bold type
Low adherence group: < 90%; medium adherence group: 90%–99.9%; high adherence group: > 99.9%
CI confidence interval, EDSS expanded disability status scale, IFN interferon, OR odds ratio, sc subcutaneous, SD standard deviation
^aData missing for 2 patients

ISSN: 1471-2377